Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
  • Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
• Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
  • Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
  • Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
• Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
  • VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
• Selective review of trials of oral SERDs in the adjuvant setting (11:27)
  • A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, MD, including the following topics:

• Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Janjigian (0:00)
• Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers — Dr Klempner(28:38)

CME information and select publications

Featuring an interview with Dr Lindsey Roeker, including the following topics:

• Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
• Safety of BTK inhibitors in older and frail patients with CLL (3:41)
• Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
• Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
• Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
• Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
• Sequencing, tolerability and future development involving pirtobrutinib (25:57)
• Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
• Clinical considerations in the management of Richter’s transformation (38:14)
• Survival outcomes and quality of life for patients with CLL (41:02)
• Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications